Clinical Trials

A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma


Study ID
AbbVie M13-367

NCT Number
NCT01794520 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0262

Principle Investigator
Dr. David Vesole

Phase
I/II

Sponsor
AbbVie


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now